Table 4.

Univariate and multivariate Cox regression analyses of the autophagy-related signature and clinical characteristics predictive of OS, DFS and PFS in each validation cohort

	Overall survival						Disease-free survival						Progression-free survival
	Univariate			Multivariate			Univariate			Multivariate			Univariate			Multivariate
	HR	p-value		HR	p-value		HR	p-value		HR	p-value		HR	p-value		HR	p-value
TCGA RNAseq cohort (n = 295)
Eight-gene signature (low-risk vs high-risk)	0.477	<0.001		0.468	<0.001		0.491	<0.001		0.517	0.001
Age (old age vs young age)	1.022	0.003		1.016	0.033		1.014	0.058
Tumor grade (G3-G4 vs G1-G2)	1.663	0.038		1.777	0.120		1.337	0.051
FIGO stage (stage III-IV vs stage I-II)	1.487	0.057					1.216	0.084
Residual tumor size (visible vs no macroscopic)	1.587	0.054					1.968	0.002		1.889	0.023
BRCA 1/2 mutation stage (mutation vs no mutation)	0.613	0.033		0.758	0.237		0.584	0.020
Lymphatic invasion (invasion vs no invasion)	1.319	0.359					1.109	0.148
Venous invasion (no invasion vs invasion)	0.927	0.830					0.603	0.311
GSE26193 cohort (n = 79)
Eight-gene signature (low-risk vs high-risk)	0.564	0.028		0.552	0.023								0.599	0.044		0.553	0.021
Tumor grade (G1-G2 vs G3-G4)	0.877	0.351											1.054	0.719
FIGO stage (stage III-IV vs stage I-II)	1.699	0.006		1.713	0.005								1.827	0.001		1.883	0.001
GSE51088 cohort (n = 106)
Eight-gene signature (low-risk vs high-risk)	0.624	0.035		0.556	0.021
Age (old age vs young age)	1.023	0.012		1.008	0.148
Tumor grade (G3-G4 vs G1-G2)	1.235	0.194
FIGO stage (stage III-IV vs stage I-II)	1.799	0.023
Disease status (not free vs free)	60.734	<0.001		66.097	<0.001

HR: hazard ratio